 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 2107 | 回復: 8 | ||||
| 當前只顯示滿足指定條件的回帖，點擊這里查看本話題的所有回帖 | ||||
mollyzhang鐵桿木蟲 (著名寫手)
|
[交流]
FDA批準強生Canagliflozin用于2型糖尿病 已有7人參與
|
|||
|
2013年1月11日訊 /生物谷BIOON/ --強生旗下的楊森制藥公司10日宣布，其糖尿病藥物canagliflozin（商品名 INVOKANA™）獲得FDA專家委員會10：5投票推薦批準，用于治療成人2型糖尿病。 Canagliflozin是一種SGLT2抑制劑藥物，能通過將葡萄糖分解后通過腎臟排出體外的方式來降低血糖，具有廣闊前景。（生物谷Bioon.com） 20130111101812190.png FDA Advisory Committee Recommends Approval of Canagliflozin for Treatment of Adults with Type 2 Diabetes RARITAN, NJ, January 10, 2013 – Janssen Research & Development, LLC (Janssen) announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 10 – 5 to recommend approval for canagliflozin, proposed trade name INVOKANA™, to treat type 2 diabetes in adult patients based on the efficacy and safety results from its comprehensive clinical development program. Canagliflozin is an investigational, oral, once-daily medication for the treatment of adult patients with type 2 diabetes. If approved by the FDA later this year, it would be the first in this new class of diabetes therapies available in the U.S. The kidneys of people with type 2 diabetes reabsorb greater amounts of glucose back into the body compared to people who do not have diabetes, which may contribute to elevated glucose levels. Canagliflozin, a selective sodium glucose co-transporter 2 (SGLT2) inhibitor, blocks the reabsorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose levels in people with diabetes who have elevated blood glucose levels. “We are pleased with the positive recommendation from the committee and look forward to working with the FDA to bring this important new therapy to patients in the U.S. to help them manage their type 2 diabetes,” said Peter Stein, M.D., Head, Metabolism Development, Diabetes Disease Area Leader, Janssen. "Today’s outcome represents an important step toward achieving that goal." Data presented at today’s advisory committee meeting included results from the comprehensive global Phase 3 clinical program, which enrolled 10,285 patients in nine studies; it is the largest late-stage development program for an investigational pharmacologic product for the treatment of type 2 diabetes submitted to health authorities to date. Canagliflozin was evaluated at 100 mg and 300 mg once-daily doses in placebo- and active comparator-controlled studies, as well as three large studies in special populations: older patients, patients with moderate renal impairment, and patients who had or were at risk for cardiovascular disease. Results showed that in addition to the improvements in glycemic control, both doses of canagliflozin were associated with weight loss and reductions in blood pressure across clinical studies. Canagliflozin was generally well tolerated. It has specific safety and tolerability issues that were well characterized in this development program (such as the genital mycotic infections, urinary tract infections) and can be well managed by the physician and by the patient for some of these issues. Janssen presented data from Phase 3 studies at the American Diabetes Association (ADA) in Philadelphia in June, at the European Association for the Study of Diabetes (EASD) in Berlin in October, and at the World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy) in Barcelona in November. The FDA will consider the advisory committee recommendation in its review of the New Drug Application (NDA) for canagliflozin that was submitted by Janssen on May 31, 2012, though the FDA is not bound to follow it. Janssen and its affiliates have rights to canagliflozin through a license agreement with Mitsubishi Tanabe Pharma Corporation. Janssen Pharmaceuticals, Inc. and its affiliates have marketing rights in North America, South America, Europe, the Middle East, Africa, Australia, New Zealand, and parts of Asia. [ Last edited by mollyzhang on 2013-1-12 at 12:52 ] |
回復此樓» 收錄本帖的淘帖專輯推薦
 新藥研發(fā) |
» 猜你喜歡
一志愿蘇州大學 生物技術(shù)與工程（086001） 初試323分，求調(diào)劑
已經(jīng)有0人回復
-
三年實驗室工作經(jīng)歷，一志愿華中農(nóng)業(yè)大學微生物，總分288求調(diào)劑
已經(jīng)有2人回復
-
藥物學論文潤色/翻譯怎么收費?
已經(jīng)有84人回復
-
中國醫(yī)藥行業(yè)發(fā)展現(xiàn)狀：標準品推動藥品檢測水平提升
已經(jīng)有1人回復
-
標準品的純度對于藥品質(zhì)量的影響有多大？
已經(jīng)有0人回復
-
070700求調(diào)劑
已經(jīng)有1人回復
-
如何制備符合技術(shù)要求的藥品標準品？
已經(jīng)有0人回復
-
對照品在藥品研發(fā)中的不可或缺性
已經(jīng)有0人回復
-
求調(diào)劑總分327
已經(jīng)有0人回復
-
標準品的分類和用途，你知道多少？
已經(jīng)有0人回復
癡夢瀟湘
木蟲 (著名寫手)
- 應助: 16 (小學生)
- 金幣: 3897.3
- 散金: 2200
- 紅花: 107
- 沙發(fā): 8
- 帖子: 2857
- 在線: 1192.5小時
- 蟲號: 1120792
- 注冊: 2010-10-12
- 性別: GG
- 專業(yè): 藥物化學
5樓2013-01-12 16:58:18
achunok
至尊木蟲 (著名寫手)
從十品
- 應助: 20 (小學生)
- 金幣: 14267.6
- 散金: 710
- 紅花: 18
- 帖子: 2251
- 在線: 222小時
- 蟲號: 233888
- 注冊: 2006-03-30
- 性別: GG
- 專業(yè): 有機合成
3樓2013-01-12 15:24:03
h_chen
鐵桿木蟲 (著名寫手)
- 應助: 33 (小學生)
- 金幣: 6522.1
- 散金: 675
- 紅花: 10
- 帖子: 1898
- 在線: 182小時
- 蟲號: 1088109
- 注冊: 2010-09-03
- 性別: GG
- 專業(yè): 天然有機化學
4樓2013-01-12 16:52:13
6樓2013-01-13 14:14:35
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 307求調(diào)劑 +12 | 超級伊昂大王 2026-03-24 | 13/650 |
|
|---|---|---|---|---|
|
[考研] 考研調(diào)劑 +5 | Sanmu-124 2026-03-26 | 5/250 |
|
|
|
[考研] 085601材料工程找調(diào)劑 +16 | oatmealR 2026-03-29 | 17/850 |
|
|
|
[考研] 332求調(diào)劑 +6 | Lyy930824@ 2026-03-29 | 6/300 |
|
|
|
[考研] 290求調(diào)劑 +3 | dfffsar 2026-03-29 | 3/150 |
|
|
|
[考研] 各位老師好，我的一志愿為北京科技大學085601材料專碩 +9 | Koxui 2026-03-28 | 9/450 |
|
|
|
[考研] 298求調(diào)劑 +3 | 種圣賜 2026-03-29 | 3/150 |
|
|
|
[考研] 一志愿太原理工安全工程300分，求調(diào)劑 +5 | 0857求調(diào)劑. 2026-03-24 | 6/300 |
|
|
|
[考研] 壓國家一區(qū)線，求導師收留，有恩必謝！ +7 | 迷人的哈哈 2026-03-28 | 7/350 |
|
|
|
[考研] 320分，材料與化工專業(yè)，求調(diào)劑 +9 | 一定上岸aaa 2026-03-27 | 13/650 |
|
|
|
[考研] 070300求調(diào)劑306分 +4 | 26要上岸 2026-03-27 | 4/200 |
|
|
|
[考研] 求調(diào)劑推薦 材料 304 +15 | 荷包蛋hyj 2026-03-26 | 15/750 |
|
|
|
[考研] 265求調(diào)劑 +8 | 小木蟲085600 2026-03-27 | 8/400 |
|
|
|
[考研] 315調(diào)劑 +4 | 0860求調(diào)劑 2026-03-26 | 5/250 |
|
|
|
[考研] 324求調(diào)劑 +5 | hanamiko 2026-03-26 | 5/250 |
|
|
|
[考研] 生物學 296 求調(diào)劑 +4 | 朵朵- 2026-03-26 | 6/300 |
|
|
|
[考研]
 085602化學工程求調(diào)劑。
+4
|
平樂樂樂 2026-03-26 | 4/200 |
|
|
|
[考研] 材料考研求調(diào)劑 +3 | Dendel 2026-03-23 | 6/300 |
|
|
|
[考研] 296求調(diào)劑 +4 | 汪�。�！ 2026-03-25 | 7/350 |
|
|
|
[考研]
 材料考研調(diào)劑生
+3
|
黃粱一夢千年 2026-03-24 | 3/150 |
|